Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: Studies in sympathectomized rats

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 1, 2010, Pages 12-18

  Augustyniak, Robert A ^a,b   Picken, Maria M ^c   Leonard, David ^d   Zhou, Xin J ^d   Zhang, Weiguo ^d   Victor, Ronald G ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Glomerulosclerosis; Pressure; Renal failure; Sympathetic nervous system

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; HYPERTENSION; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NONHUMAN; PROTEINURIA; RAT; SYMPATHECTOMY; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; TELEMETRY; URINARY EXCRETION;

ANIMALS; ANIMALS, NEWBORN; BLOOD PRESSURE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GUANETHIDINE; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; NEPHRECTOMY; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHECTOMY, CHEMICAL; SYMPATHETIC NERVOUS SYSTEM;

EID: 74049139130     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05253.x     Document Type: Article

References (39)

1. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Pathogenesis, clinical relevance, and treatment. Kidney Int. 2004 65 : 1568 1576.
2. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006 70 : 1905 1913.
3. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: Why is it so resistant to treatment? Kidney Int. 2006 69 : 967 973.
4. Agrawal B, Wolf K, Berger A, Luft FC. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J. Hum. Hypertens. 1996 10 : 551 555.
5. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: A multicentre randomised study. Int. J. Clin. Pract 1999 53 : 519 522.
6. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: A multicenter, randomized, open-label, controlled study versus atenolol. Adv. Ther. 1995 12 : 212 221.
7. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002 105 : 1354 1359. (Pubitemid 34260428)
8. Converse RL Jr., Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 1992 327 : 1912 1918.
9. Neumann J, Ligtenberg G, Klein IH et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007 49 : 506 510. (Pubitemid 46263234)
10. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N. Engl. J. Med. 1999 340 : 1321 1328.
11. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995 25 : 878 882.
12. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am. J. Kidney Dis. 1995 26 : 861 865.
13. Yuhara M, Ikeda T, Toya Y, Sakurai J, Gomi T. Participation of the sympathetic nervous system in hypertension in rats with subtotal renal ablation. J. Hypertens. 1989 7 : 443 446.
14. Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 2000 11 : 1469 1478.
15. Amann K, Koch A, Hofstetter J et al. Glomerulosclerosis and progression: Effect of subantihypertensive doses of alpha and beta blockers. Kidney Int. 2001 60 : 1309 1323.
16. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J. Am. Soc. Nephrol. 1994 4 : 2023 2031.
17. ω-nitro-l-arginine methyl ester. Hypertension 1997 30 : 64 70.
18. Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995 26 : 691 695.
19. Dobbins RL, Szczepaniak LS, Zhang W, McGarry JD. Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin infusion. Am. J. Physiol. Endocrinol. Metab. 2003 284 : E778 87.
20. Johnson EM Jr., Cantor E, Douglas JR Jr. Biochemical and functional evaluation of the sympathectomy produced by the administration of guanethidine to newborn rats. J. Pharmacol. Exp. Ther. 1975 193 : 503 512.
21. Johnson EM Jr., O'Brien F, Werbitt R. Modification and characterization of the permanent sympathectomy produced by the administration of guanethidine to newborn rats. Eur. J. Pharmacol. 1976 37 : 45 54.
22. Levin BE, Sullivan AC. Dietary obesity and neonatal sympathectomy. II. Thermoregulation and brown adipose metabolism. Am. J. Physiol. 1984 247 : R988 94.
23. Powley TL, Walgren MC, Laughton WB. Effects of guanethidine sympathectomy on ventromedial hypothalamic obesity. Am. J. Physiol. 1983 245 : R408 20.
24. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 57 : 1651 1661.
25. Ludbrook J. Comparing methods of measurements. Clin. Exp. Pharmacol. Physiol. 1997 24 : 193 203.
26. Kermack KA, Haldane JB. Organic correlation and allometry. Biometrika 1950 37 : 30 41.
27. McGrath BP, Tiller DJ, Bune A, Chalmers JP, Korner PI, Uther JB. Autonomic blockade and the Valsalva maneuver in patients on maintenance hemodialysis: A hemodynamic study. Kidney Int. 1977 12 : 294 302.
28. Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C. Norepinephrine-related mechanism in hypertension accompanying renal failure. Kidney Int. 1985 28 : 814 822.
29. Griffin KA, Picken M, Bidani AK. Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int. 1994 46 : 1010 1018.
30. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J. Clin. Invest. 1995 96 : 793 800.
31. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Castrodeza Sanz JJ. Influence of sympathetic activity on blood pressure and vascular damage evaluated by means of urinary albumin excretion. J. Clin. Hypertens. 2006 8 : 619 624.
32. Rao F, Wessel J, Wen G et al. Renal albumin excretion: Twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertension 2007 49 : 1015 1031.
33. Veelken R, Vogel EM, Hilgers K et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J. Am. Soc. Nephrol. 2008 19 : 1371 1378.
34. Bidani AK, Griffin KA, Picken M, Lansky DM. Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am. J. Physiol. 1993 265 : F391 8.
35. Hamar P, Kokeny G, Liptak P et al. The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model. Nephron Exp. Nephrol. 2007 105 : E124 36.
36. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J. Am. Soc. Nephrol. 2006 17 : 2100 2105. (Pubitemid 44141898)
37. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004 110 : 32 5.
38. Marin R, Rodriguez P, Tranche S et al. Prevalence of abnormal urinary albumin excretion rate in hypertensive patients with impaired fasting glucose and its association with cardiovascular disease. J. Am. Soc. Nephrol. 2006 17 (Suppl. 3 S178 88.
39. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009 373 : 1275 1281.